Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Metformin — a cardiovascular moderator of DPP4 inhibitors?

Nature Reviews Endocrinology volume 14, pages 8–9 (2018)Cite this article

Subjects

Three cardiovascular outcome trials failed to show superiority of DPP4 inhibitors compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk, a rather disappointing finding. Now, a post hoc subgroup analysis suggests that patients treated with metformin at baseline might benefit from DPP4 inhibitors in contrast with metformin non-users.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Scheen, A. J. Cardiovascular effects of gliptins. Nat. Rev. Cardiol. 10, 73–84 (2013).

    Article  CAS  Google Scholar 

  2. Standl, E. et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 5, 391–402 (2017).

    Article  Google Scholar 

  3. White, W. B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335 (2013).

    Article  CAS  Google Scholar 

  4. Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326 (2013).

    Article  CAS  Google Scholar 

  5. Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242 (2015).

    Article  CAS  Google Scholar 

  6. Crowley, M. J. et al. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Care http://dx.doi.org/10.2337/dc17-1528 (2017).

  7. Hernandez, A. V. et al. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am. Heart J. 151, 257–264 (2006).

    Article  Google Scholar 

  8. Sun, X. et al. How to use a subgroup analysis: users' guide to the medical literature. JAMA 311, 405–411 (2014).

    Article  CAS  Google Scholar 

  9. Migoya, E. M. et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin. Pharmacol. Ther. 88, 801–808 (2010).

    Article  CAS  Google Scholar 

  10. Wang, F. et al. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore) 96, e7638 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Diabetes, Department of Medicine, Belgium; and the Division of Clinical Pharmacology, Nutrition and Metabolic Disorders, CHU Liège, Liège B-4000, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège B-4000, Belgium.,

    André J. Scheen

  2. and the Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège B-4000, Belgium.,

    André J. Scheen

Authors
  1. André J. Scheen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to André J. Scheen.

Ethics declarations

Competing interests

The author declares that no competing interests are directly relevant to the content of this manuscript. A.J.S. has received lecturer,scientific adviser and clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, NovoNordisk, Sanofi and Servier. A.J.S. was a clinical investigator in the TECOS, LEADER, EMPA-REG OUTCOME and CANVAS-R trials.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scheen, A. Metformin — a cardiovascular moderator of DPP4 inhibitors?. Nat Rev Endocrinol 14, 8–9 (2018). https://doi.org/10.1038/nrendo.2017.154

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2017.154

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing